MedTrace Logo

Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients

NCT01168505 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-05-21

No results posted yet for this study

Summary

Study to evaluate the efficacy of intravenous iron supplementation in the prevention of anemia in patients receiving (neo)adjuvant breast cancer regimens.

Conditions

Interventions

DRUG

ferric hydroxide saccharate

single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses

Sponsors & Collaborators

  • Fundação Faculdade de Medicina

    collaborator OTHER

  • Instituto do Cancer do Estado de São Paulo

    lead OTHER

Principal Investigators

  • Paulo Hoff, MD Professor · Instituto do Câncer do Estado de São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01168505 on ClinicalTrials.gov